View Older Stories View More Recent Stories

Dec 6, 2021 05:18AM Merck (MRK) Reports FDA Approval of KEYTRUDA as Adjuvant Treatment for Adult and Pediatric Patients With Stage IIB or IIC Melanoma Following Complete Resection
Dec 3, 2021 06:15PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
Dec 1, 2021 06:46AM Merck (MRK) Announces U.S. FDA Accepts for Priority Review the SBLA for VAXNEUVANCE for Use in Infants and Children
Dec 1, 2021 06:45AM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
Nov 30, 2021 05:54PM Merck (MRK), Ridgeback Confirm FDA Advisory Committee Voted 13-10 in Favor of COVID-19 Antiviral Drug Molnupiravir
Nov 30, 2021 05:51PM Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
Nov 30, 2021 02:48PM Merck Announces First-Quarter 2022 Dividend
Nov 30, 2021 06:45AM Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Nov 30, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Nov 30, 2021 06:30AM FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority
Nov 29, 2021 09:30AM Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
Nov 29, 2021 06:50AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 06:50AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 06:46AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC
Nov 29, 2021 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 29, 2021 05:52AM Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 26, 2021 06:46AM Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Nov 26, 2021 06:45AM Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Nov 24, 2021 06:45AM Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 22, 2021 06:45AM Merck (MRK) Completes Acquisition of Acceleron Pharma (XLRN)
Nov 22, 2021 06:45AM Merck Completes Acquisition of Acceleron Pharma Inc.
Nov 22, 2021 06:26AM Merck (MRK) Completes Tender Offer to Acquire Acceleron Pharma (XLRN)
Nov 19, 2021 06:06PM Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
Nov 18, 2021 07:21PM Merck (MRK) Stops Dosing in Phase 2 Trial of MK-8507 and Islatravir for the Treatment of HIV-1
Nov 18, 2021 05:57PM Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
Nov 18, 2021 09:00AM New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of People Living With Cancer, Affecting Mental Health and Relationships
Nov 18, 2021 06:46AM Merck's (MRK) KEYTRUDA Granted FDA Approval as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Nov 18, 2021 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Nov 17, 2021 06:46AM Merck (MRK) Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma (XLRN)
Nov 17, 2021 06:45AM Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Nov 17, 2021 06:01AM Merck (MRK) and Ridgeback to Report Phase 3 Data for Molnupiravir
Nov 17, 2021 06:00AM Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
Nov 17, 2021 01:05AM Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
Nov 11, 2021 06:45AM Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Eve
Nov 10, 2021 05:05PM IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
Nov 10, 2021 08:05AM Merck (MRK), Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
Nov 10, 2021 08:00AM Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
Nov 9, 2021 06:04AM Merck (MRK) and Ridgeback Announce Additional Purchase of 1.4M Courses of Molnupiravir by the US Government
Nov 9, 2021 06:00AM Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in A
Nov 8, 2021 04:32PM Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and Austria
Nov 8, 2021 04:30PM Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
Nov 4, 2021 06:46AM Merck's (MRK) Molnupiravir Approved in the UK
Nov 4, 2021 06:40AM Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
Oct 31, 2021 01:35PM New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
Oct 29, 2021 04:34PM Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Oct 28, 2021 09:00AM MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
Oct 28, 2021 06:30AM Merck Announces Third-Quarter 2021 Financial Results
Oct 27, 2021 06:45AM Merck (MRK) Reports New Data from Phase 2b Clinical Trial Evaluating Efficacy and Safety of Islatravir in Combination With Doravirine
Oct 27, 2021 06:45AM Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2
Oct 27, 2021 06:00AM Merck (MRK) Announces License Agreement with The Medicines Patent Pool for Molnipiravir
View More Recent Stories View Older Stories